Statin therapy reduces oxidized low density lipoprotein level, a risk factor for stroke outcome

Critical Care

Volumn 18, Issue 1, 2014, Pages

  Tsai, Nai Wen ^a   Lee, Lian Hui ^a   Huang, Chi Ren ^a   Chang, Wen Neng ^a   Chang, Ya Ting ^a   Su, Yu Jih ^a,b   Chiang, Yi Fang ^a   Wang, Hung Chen ^a   Cheng, Ben Chung ^a,b   Lin, Wei Che ^a   Kung, Chia Te ^a   Su, Chih Min ^a,b   Lin, Yu Jun ^a,b   Lu, Cheng Hsien ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

AGED; ANTAGONISTS AND INHIBITORS; BLOOD; FEMALE; HUMAN; MALE; MIDDLE AGED; RISK FACTOR; STROKE; TREATMENT OUTCOME;

AGED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84892420349     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13695     Document Type: Article

References (36)

1. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 2001, 15:2073-2084. 10.1096/fj.01-0273rev, 11641234.
2. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002, 8:1227-1234. 10.1038/nm1102-1227, 12411949.
3. Cherubini A, Ruggiero C, Polidori MC, Mecocci P. Potential markers of oxidative stress in stroke. Free Radic Biol Med 2005, 39:841-852. 10.1016/j.freeradbiomed.2005.06.025, 16140205.
4. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R, Matsuo T, Itabe H, Takano T, Tsukamoto Y, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001, 103:1955-1960. 10.1161/01.CIR.103.15.1955, 11306523.
5. Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, Shimamura K, Kimura J, Michishita I, Suzuki T, Nagai R. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 2000, 20:2243-2247. 10.1161/01.ATV.20.10.2243, 11031210.
6. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA 2008, 299:2287-2293. 10.1001/jama.299.19.2287, 2562739, 18492970.
7. Alberts AW. Discovery, biochemistry and biology of lovastatin. Am J Cardiol 1988, 62:10J-15J. 10.1016/0002-9149(88)90002-1, 3055919.
8. Kwak BR, Mach F. Statins inhibit leukocyte recruitment: new evidence for their anti-inflammatory properties. Arterioscler Thromb Vasc Biol 2001, 21:1256-1258.
9. Tailor A, Lefer DJ, Granger DN. HMG-CoA reductase inhibitor attenuates platelet adhesion in intestinal venules of hypercholesterolemic mice. Am J Physiol Heart Circ Physiol 2004, 286:H1402-H1407.
10. Azar RR, Waters DD. PRINCE's prospects: statins, inflammation, and coronary risk. Am Heart J 2001, 141:881-883. 10.1067/mhj.2001.115298, 11376298.
11. Fang CH, Li JJ, Hui RT. Statin, like aspirin, should be given as early as possible in patients with acute coronary syndrome. Med Hypotheses 2005, 64:192-196. 10.1016/j.mehy.2004.06.018, 15533640.
12. Tsai NW, Lin TK, Chang WN, Jan CR, Huang CR, Chen SD, Cheng KY, Chiang YF, Wang HC, Yang TM, Lin YJ, Lin WC, Chang HW, Lee LH, Lu CH. Statin pre-treatment is associated with lower platelet activity and favorable outcome in patients with acute non-cardio-embolic ischemic stroke. Crit Care 2011, 15:R163. 10.1186/cc10303, 3387600, 21740551.
13. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24:35-41. 10.1161/01.STR.24.1.35, 7678184.
14. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011, 42:227-276. 10.1161/STR.0b013e3181f7d043, 20966421.
15. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, Degraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 2006, 37:1583-1633. 10.1161/01.STR.0000223048.70103.F1, 16675728.
16. Sulter G, Steen C, De Keyser J. Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 1999, 30:1538-1541. 10.1161/01.STR.30.8.1538, 10436097.
17. Uno M, Kitazato KT, Nishi K, Itabe H, Nagahiro S. Raised plasma oxidised LDL in acute cerebral infarction. J Neurol Neurosurg Psychiatry 2003, 74:312-316. 10.1136/jnnp.74.3.312, 1738343, 12588914.
18. Sarkar PD, Rautaray SS. Oxidized LDL and paraoxanase status in ischemic stroke patients. Indian J Physiol Pharmacol 2008, 52:403-407.
19. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998, 98:1487-1494. 10.1161/01.CIR.98.15.1487, 9769301.
20. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB. Oxidized phospholipids, Lp (a) lipoprotein, and coronary artery disease. N Engl J Med 2005, 353:46-57. 10.1056/NEJMoa043175, 16000355.
21. Walder CE, Green SP, Darbonne WC, Mathias J, Rae J, Dinauer MC, Curnutte JT, Thomas GR. Ischemic stroke injury is reduced in mice lacking a functional NADPH oxidase. Stroke 1997, 28:2252-2258. 10.1161/01.STR.28.11.2252, 9368573.
22. Guldiken B, Guldiken S, Turgut B, Turgut N, Demir M, Celik Y, Arikan E, Tugrul A. The roles of oxidized low-density lipoprotein and interleukin-6 levels in acute atherothrombotic and lacunar ischemic stroke. Angiology 2008, 59:224-229. 10.1177/0003319707304134, 18388043.
23. Polidori MC, Frei B, Cherubini A, Nelles G, Rordorf G, Keaney JF, Schwamm L, Mecocci P, Koroshetz WJ, Beal MF. Increased plasma levels of lipid hydroperoxides in patients with ischemic stroke. Free Radic Biol Med 1998, 25:561-567. 10.1016/S0891-5849(98)00085-9, 9741593.
24. Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, Nagahiro S. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol 2002, 22:1649-1654. 10.1161/01.ATV.0000033829.14012.18, 12377744.
25. Nakajima K, Nakano T, Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta 2006, 367:36-47. 10.1016/j.cca.2005.12.013, 16448638.
26. Zeljkovic A, Vekic J, Spasojevic-Kalimanovska V, Jelic-Ivanovic Z, Bogavac-Stanojevic N, Gulan B, Spasic S. LDL and HDL subclasses in acute ischemic stroke: prediction of risk and short-term mortality. Atherosclerosis 2010, 210:548-554. 10.1016/j.atherosclerosis.2009.11.040, 20022325.
27. Chen NG, Azhar S, Abbasi F, Carantoni M, Reaven GM. The relationship between plasma glucose and insulin responses to oral glucose, LDL oxidation, and soluble intercellular adhesion molecule-1 in healthy volunteers. Atherosclerosis 2000, 152:203-208. 10.1016/S0021-9150(99)00460-8, 10996356.
28. Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J, Goodpaster B, Harris TB. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 2004, 53:1068-1073. 10.2337/diabetes.53.4.1068, 15047623.
29. Maziere C, Morliere P, Santus R, Marcheux V, Louandre C, Conte MA, Maziere JC. Inhibition of insulin signaling by oxidized low density lipoprotein. Protective effect of the antioxidant Vitamin E. Atherosclerosis 2004, 175:23-30.
30. Nakhjavani M, Khalilzadeh O, Khajeali L, Esteghamati A, Morteza A, Jamali A, Dadkhahipour S. Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol. Lipids 2010, 45:321-327. 10.1007/s11745-010-3401-8, 20224977.
31. Idicula TT, Brogger J, Naess H, Waje-Andreassen U, Thomassen L. Admission C-reactive protein after acute ischemic stroke is associated with stroke severity and mortality: the 'Bergen stroke study'. BMC Neurol 2009, 9:18. 10.1186/1471-2377-9-18, 2680802, 19400931.
32. Makita S, Nakamura M, Satoh K, Tanaka F, Onoda T, Kawamura K, Ohsawa M, Tanno K, Itai K, Sakata K, Okayama A, Terayama Y, Yoshida Y, Ogawa A. Serum C-reactive protein levels can be used to predict future ischemic stroke and mortality in Japanese men from the general population. Atherosclerosis 2009, 204:234-238. 10.1016/j.atherosclerosis.2008.07.040, 18790479.
33. Tsai NW, Lee LH, Huang CR, Chang WN, Chen SD, Wang HC, Lin YJ, Lin WC, Chiang YF, Lin TK, Cheng BC, Su YJ, Kung CT, Hung SH, Chang HW, Lu CH. The association of statin therapy and high-sensitivity C-reactive protein level for predicting clinical outcome in acute non-cardioembolic ischemic stroke. Clin Chim Acta 2012, 413:1861-1865. 10.1016/j.cca.2012.07.021, 22892175.
34. Zhao J, Qi R, Li R, Wu W, Gao X, Bao L, Lu S. Protective effects of aspirin against oxidized LDL-induced inflammatory protein expression in human endothelial cells. J Cardiovasc Pharmacol 2008, 51:32-37. 10.1097/FJC.0b013e318159ebaf, 18209566.
35. Honjo T, Yamaoka-Tojo M, Inoue N. Pleiotropic effects of ARB in vascular metabolism-focusing on atherosclerosis-based cardiovascular disease. Curr Vasc Pharmacol 2011, 9:145-152. 10.2174/157016111794519273, 21143170.
36. Li L, Renier G. The oral anti-diabetic agent, gliclazide, inhibits oxidized LDL-mediated LOX-1 expression, metalloproteinase-9 secretion and apoptosis in human aortic endothelial cells. Atherosclerosis 2009, 204:40-46. 10.1016/j.atherosclerosis.2008.08.008, 18801483.